共 16 条
[1]
Sung C.O., Ahn G., Song S.Y., Atypical leiomyomas of the uterus with long-term follow-up after myomectomy with immunohistochemical analysis for p16INK4A, p53, Ki-67, estrogen receptors, and progesterone receptors, Int J Gynecol Pathol, 28, 6, pp. 529-534, (2009)
[2]
Prayson R.A., Hart W.R., Pathologic considerations of uterine smooth muscle tumors, Obstet Gynecol Clin North Am, 22, 4, pp. 637-657, (1995)
[3]
Fattaneh A., Tavassoli Peter Devilee: Pathology and Genetics of Tumours of the Breast and Female Genital Organs, (2003)
[4]
Ip P.P., Cheung A.N., Clement P.B., Uterine smooth muscle tumors of uncertain malignant potential (STUMP): A clinicopathologic analysis of 16 cases, Am J Surg Pathol, 33, 7, pp. 992-1005, (2009)
[5]
Bodner-Adler B., Bodner K., Czerwenka K., Expression of p16 protein in patients with uterine smooth muscle tumors: An immunohistochemical analysis, Gynecol Oncol, 96, 1, pp. 62-66, (2005)
[6]
O'Neill C.J., McBride H.A., Connolly L.E., Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential, Histopathology, 50, 7, pp. 851-858, (2007)
[7]
Atkins K.A., Arronte N., Darus C.J., The use of p16 in enhancing the histologic classification of uterine smooth muscle tumors, Am J Surg Pathol, 32, 1, pp. 98-102, (2008)
[8]
Ly A., Mills A.M., McKenney J.K., Atypical leiomyomas of the uterus: A clinicopathologic study of 51 cases, Am J Surg Pathol, 37, 5, pp. 643-649, (2013)
[9]
Mills A.M., Ly A., Balzer B.L., Cell cycle regulatory markers in uterine atypical leiomyoma and leiomyosarcoma: Immunohistochemical study of 68 cases with clinical follow-up, Am J Surg Pathol, 37, 5, pp. 634-642, (2013)
[10]
Unver N.U., Acikalin M.F., Oner U., Differential expression of P16 and P21 in benign and malignant uterine smooth muscle tumors, Arch Gynecol Obstet, 284, 2, pp. 483-490, (2011)